The risk is, and has always been that in the same sense that FDA approval validates the platform if it gets pulled up on the malinancies, liver enzymes or any other matter & the FDA swings the gavel against it the pendelum swings the other way & uncertainty surrounds it. Always have to remember ISIS was founded 23 years ago & to date has only had 1 approved drug for HIV which was superseded by others not to long after approved. It's been a long battle for the company to break through & while yes there are a long line in development with a range of big pharma partners it still comes back to the fact that as of yet nothing signifcant has yet been passed by the FDA & put to market.
What the FDA hands out is a big play, in my opinion & it is only my opinion but if it gets knocked back or made to conduct further trials the effect on share price will be far more signifcant than if it is approved.
ANP Price at posting:
14.0¢ Sentiment: None Disclosure: Held
